Novo Nordisk
Also known as: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Novo Nordic | NOVO NORDISK | Novo Nordisk A/S | Novo Nordisk Inc. | NOVO NORDISK INC | Novo Nordisk India Ltd | Novo Nordisk India Private Ltd. | Novo Nordisk Pharma Ltd | Novo Nordisk Pharma Ltd. | The Novo Nordic Foundation | The Novo Nordisk Foundation | The Novo Nordisk Foundation Center for Basic Metabolic Research | The Novo Nordisk UK Research Foundation
Highest phase reached
Phase 4
First clinical trial
Jan 1, 1989First marketed drug
Jan 1, 1989First NDA
Mar 25, 1999Last known activity
Aug 4, 2026
Timeline
2010s
- Jan 1, 2013
Xellia Pharmaceuticals— Acquired
- Aug 27, 2015
Calibrium— Acquired
- Aug 27, 2015
MB2— Acquired
- Aug 17, 2018
Ziylo— Acquired
- Dec 12, 2018
Berkeley Lights— Acquired
2020s
- Jun 11, 2020
Corvidia Therapeutics— Acquired
- Aug 28, 2020
somapacitan— Marketing Organization
- Aug 28, 2020
somapacitan— NDA Secondary Org
- Aug 28, 2020
somapacitan— NDA Organization
- Nov 6, 2020
Emisphere Technologies, Inc.— Acquired
- Mar 29, 2021
Altasciences Company Inc.— Acquired
- Nov 18, 2021
Dicerna Pharmaceuticals, Inc.— Acquired
- Sep 1, 2022
Forma Therapeutics, Inc.— Acquired
- Aug 10, 2023
Inversago Pharma— Acquired
- Aug 10, 2023
Inversago Pharma Inc.— Acquired
- Aug 30, 2023
Ancora Health— Acquired
- Sep 18, 2023
Paratek Pharmaceuticals Inc— Acquired
- Feb 5, 2024
Catalent— Acquired - Mar 25, 2024
Cardior Pharmaceuticals GmbH— Acquired
- Oct 15, 2025
Akero Therapeutics, Inc— Acquired
Drugs by trial phase (317 distinct, 1315 trials)
Phase 4 (58 own, 6 via acquisition)
Phase 3 (15 own, 15 via acquisition)
Phase 2 (37 own, 30 via acquisition)
Phase 1 (62 own, 75 via acquisition)
Indications
Studied for
- Adrenal Insufficiency
- Aging, Premature
- Albuminuria
- Anorexia
- Anorexia Nervosa
- Apnea
- Arteriosclerosis
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Atherosclerosis
- Athletic Injuries
- Atrophic Vaginitis
- Atrophy
- Binge-Eating Disorder
- Bipolar Disorder
- Blood Coagulation Disorders
- Body Weight
- Body Weight Changes
- Bone Diseases, Metabolic
- Brain Concussion
- Brain Injuries
- Brain Injuries, Traumatic
- Bulimia
- Carcinoma
- Carcinoma, Ovarian Epithelial
- Carcinoma, Renal Cell
- Cardiovascular Diseases
- Cerebral Hemorrhage
- Chemical and Drug Induced Liver Injury
- Communicable Diseases
- Critical Illness
- Crohn Disease
- Cystic Fibrosis
- Cystitis
- Dengue
- Depression
- Diabetes Complications
- Diabetes, Gestational
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Nephropathies
- Diabetic Neuropathies
- Digestive System Diseases
- Diphtheria
- Disease
- Dwarfism
- Dwarfism, Pituitary
- Dysbiosis
- Emergencies
- Endocrine System Diseases
- Fatty Liver
- Feeding and Eating Disorders
- Fetal Growth Retardation
- Fever
- Fibrosis
- Fractures, Bone
- Gastrointestinal Diseases
- Genetic Diseases, Inborn
- Glucose Intolerance
- Gonadal Dysgenesis
- Growth Disorders
- Heart Diseases
- Heart Failure
- Hematoma
- Hemophilia A
- Hemophilia B
- Hemorrhage
- Hemorrhagic Disorders
- Hemorrhagic Fevers, Viral
- Hemostatic Disorders
- HIV Infections
- Hypercholesterolemia
- Hyperglycemia
- Hypertension
- Hypoglycemia
- Hypopituitarism
- Hypoxia
- Infarction
- Infections
- Inflammation
- Insulin Resistance
- Kidney Diseases
- Kidney Failure, Chronic
- Leukemia
- Leukemia, Lymphoid
- Liver Cirrhosis
- Liver Diseases
- Lung Diseases
- Lung Diseases, Obstructive
- Lupus Erythematosus, Systemic
- Lymphoma
- Measles
- Melanoma
- Metabolic Syndrome
- Mood Disorders
- Muscular Atrophy
- Muscular Atrophy, Spinal
Marketed drugs (35)
Subsidiaries (19 direct, 28 total across the full acquisition tree)
- Akero Therapeutics, Inc
- Altasciences Company Inc.
- Ancora Health
- Berkeley Lights
- Calibrium
- Cardior Pharmaceuticals GmbH
- Catalent
- Corvidia Therapeutics
- Dicerna Pharmaceuticals, Inc.
- Emisphere Technologies, Inc.
- Forma Therapeutics, Inc.
- Inversago Pharma
- Inversago Pharma Inc.
- MB2
- Nordisk
- Novo
- Paratek Pharmaceuticals Inc
- Xellia Pharmaceuticals
- Ziylo
- Accucaps Industries L2
- Juniper Pharmaceuticals, Inc. L2
- OptiNose AS L2
- Paragon Bioservices L2
- Pharmatek Laboratries L2
- Transcept Pharmaceuticals L2
- WCCT Global L2
- Medelis Inc. L3
- Novacea L3
Recent trials (50)
- NCT04921956Lead sponsorN/A—
- NCT05993416Lead sponsorN/A—
- NCT07282613Lead sponsorPhase 3Aug 4, 2026
- NCT07282613OfficialPhase 3Aug 4, 2026
- NCT07253285Lead sponsorPhase 3Jan 8, 2026
- NCT07253285OfficialPhase 3Jan 8, 2026
- NCT07246421CollaboratorN/AJan 1, 2026
- NCT07301034Lead sponsorPhase 3Dec 18, 2025
- NCT07301034OfficialPhase 3Dec 18, 2025
- NCT07305805Lead sponsorPhase 1Dec 15, 2025
- NCT07305805OfficialPhase 1Dec 15, 2025
- NCT07276282CollaboratorPhase 3Dec 11, 2025
- NCT07271251Lead sponsorPhase 3Dec 1, 2025
- NCT07271251OfficialPhase 3Dec 1, 2025
- NCT07270731Lead sponsorPhase 1Nov 25, 2025
Details
- Founded
- Copenhagen, DK Jan 1, 1989
- First NDA
- Mar 25, 1999
- Last known activity
- Aug 4, 2026
Designations held
- Orphan drug
- Priority review
- Breakthrough therapy